Article

FDA Podcast: The Dangers Associated with Propoxyphene

A pharmacist with the FDA explains the reasoning behind the concerns with propoxyphene.

Mary Kremzner, a pharmacist in the Division of Drug Information with the FDA, discusses the recent recommendation made by the FDA to medical professionals to stop administering propoxyphene.

Click here to access this third-party resource.

Related Videos
Peter Lio, MD: Minimizing Painful Pediatric Dermatologic Procedures
Educating Third-Year Students on Opioid Use Disorder, Pain Management
Related Content
Crisugabalin Provides Significant Pain Improvements in Adults with Postherpetic Neuralgia
October 4th 2024

Crisugabalin Provides Significant Pain Improvements in Adults with Postherpetic Neuralgia

Chelsie Derman
Revising the CDC Clinical Guideline for Prescribing Opioids
March 10th 2022

Revising the CDC Clinical Guideline for Prescribing Opioids

Giuliana Grossi
Opioid Pain Treatment Raises Dependence and Use Disorder Rates
August 8th 2024

Opioid Pain Treatment Raises Dependence and Use Disorder Rates

Chelsie Derman
Alan Kaye, MD, PhD: Treating Pain Traditionally and with Alternate Therapies
September 22nd 2020

Alan Kaye, MD, PhD: Treating Pain Traditionally and with Alternate Therapies

Samara Rosenfeld
FDA Issues a CRL for Ketamine’s Abbreviated New Drug Application
April 29th 2024

FDA Issues a CRL for Ketamine’s Abbreviated New Drug Application

Chelsie Derman
FDA Issues Warning for Topical Analgesics with High Levels of Lidocaine
March 26th 2024

FDA Issues Warning for Topical Analgesics with High Levels of Lidocaine

Kevin Kunzmann
© 2024 MJH Life Sciences

All rights reserved.